Which psa test is best

Prostatitis and its Management. Eur Urol Suppl. Published Accessed January 4, Board of Community Health Councils. NHS Complaints procedure - how we can help. Accessed July 29, Cancer Research UK. Cancer incidence for common cancers Accessed December 12, Prostate cancer incidence statistics: by age Prostate cancer incidence statistics: Lifetime risk of prostate cancer Accessed July 6, Cao Y, Ma J. Cancer Prev Res Phila Pa.

Acute Bacterial Prostatitis: Diagnosis and Management. Am Fam Physician. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT Prostate testing for cancer and Treatment study. BJU Int. Genetic markers a landscape in prostate cancer.

Mutat Res Mutat Res. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies.

Ann Oncol. September The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol. Clin Genitourin Cancer. Am J Roentgenol. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Prospective study on metabolic factors and risk of prostate cancer: Metabolic Factors and Prostate Cancer. Prostate cancer screening with prostate-specific antigen PSA test: a systematic review and meta-analysis.

Jones AL, Chinegwundoh F. Update on prostate cancer in black men within the UK. March Ethnic differences in prostate cancer. Br J Cancer. False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis.

Int J Clin Pract. The effects of prostatic manipulation on prostate-specific antigen levels. J Clin Oncol. Int Neurourol J. May Treatment of Bacterial Prostatitis. Clin Infect Dis. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England — BMC Med.

Systematic review of complications of prostate biopsy. Detection of prostate cancer following gender reassignment. Lower urinary tract symptoms in men: assessment and management.

June National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management. NICE guideline Prostate Cancer: diagnosis and treatment. Full guideline Suspected cancer: recognition and referral.

NICE Guideline June , updated NHS Scotland complaints. September S Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study.

J Gay Lesbian Psychother. Make a complaint against the health service nidirect. Published December 12, Pre-and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer.

Ann Clin Biochem. Prostate Cancer UK. Costs may include:. If you are age 50 to 74, you should discuss the PSA test with your doctor. Ask about the possible risks and benefits. Men under 50 or over 75 rarely need a PSA test, unless they have a high risk for prostate cancer.

This report is for you to use when talking with your healthcare provider. It is not a substitute for medical advice and treatment. Use of this report is at your own risk. Developed in cooperation with the American Academy of Family Physicians.

Additional Resources. The prostate health index PHI is one such test that is a more accurate blood test and measures your risk for having prostate cancer. If you score low on the PHI test, your doctor may recommend monitoring you over time to see if your levels rise enough to cause concern. This test detects the gene PCA3 in your urine and can also help your doctor better assess your prostate cancer risk. But data suggest that when cancer is present, the PCA3 will be positive 80 percent of the time.

This test can also help your doctor determine whether a biopsy is necessary. Both of these new tests are more accurate than the PSA test. Your doctor may recommend one or more than one, based on the specifics of your case. Advancements here, too, are ensuring more accuracy, so there is less risk of misdiagnosis. In a prostate biopsy, doctors have traditionally taken eight to 12 needle biopsies along the prostate, in a random sample.

Due to imaging improvements, doctors can now use MRI imaging technology before a biopsy to look for areas in the prostate that are suspicious for cancer.